BSE: 544293 | NSE: SURAKSHA | Hospital & Healthcare Services | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Suraksha Diagnostic Ltd is a good quality company.
The key valuation ratios of Suraksha Diagnostic Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Suraksha Diagnostic Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'11 | Mar'12 | Mar'13 | Mar'15 | Mar'16 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 0% | 0% | 0% | 16.8% | 16.1% | 20.2% | 6% | 22.7% | 9.6% | 22.9% | - |
| Value Creation Index ⓘ | NA | NA | NA | 0.2 | 0.2 | 0.4 | -0.6 | 0.6 | -0.3 | 0.6 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 0 | 0 | 0 | 70.2 | 99.1 | 158 | 140 | 223 | 190 | 219 | 219 |
| Sales YoY Gr. | - | NA | NA | NA | 41.2% | 58.9% | -11.1% | 59.4% | -14.8% | 15% | - |
| Adj EPS ⓘ | 0 | 0 | 0 | 109.3 | 78.4 | 217.5 | 115.1 | 358.5 | 119.1 | 372.1 | 4.5 |
| YoY Gr. | - | NA | NA | NA | -28.3% | 177.3% | -47.1% | 211.4% | -66.8% | 212.4% | - |
| BVPS (₹) ⓘ | 0 | 0 | 0 | 695.5 | 775.2 | 1,712.5 | 1,805.7 | 2,149.9 | 2,236.2 | 2,576.5 | 196.6 |
| Adj Net Profit ⓘ | 0 | 0 | 0 | 7.5 | 5.4 | 15 | 7.9 | 24.7 | 8.2 | 25.7 | 24 |
| Cash Flow from Ops. ⓘ | 0 | 0 | 0 | 19.5 | 13.5 | 31.3 | 23.5 | 42.3 | 44.1 | 60.5 | - |
| Debt/CF from Ops. ⓘ | 0 | 0 | 0 | 1.5 | 3.1 | 0.4 | 0.7 | 0.5 | 0.3 | 0.1 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | 17.2% | 16% | 15% | ||||
| Adj EPS ⓘ | NA | 36.5% | 47.8% | 212.4% | ||||
| BVPSⓘ | NA | 27.2% | 12.6% | 15.2% | ||||
| Share Price | - | - | - | - | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'11 | Mar'12 | Mar'13 | Mar'15 | Mar'16 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 0 | 0 | 0 | 15.3 | 10.4 | 17.2 | 6.5 | 17.9 | 5.4 | 15.3 | 0.3 |
| Op. Profit Mgn % ⓘ | 0 | 0 | 0 | 24.8 | 22.2 | 21.7 | 17.9 | 22.2 | 24.6 | 33.4 | 34.7 |
| Net Profit Mgn % ⓘ | 0 | 0 | 0 | 10.7 | 5.5 | 9.5 | 5.7 | 11.1 | 4.1 | 11.5 | 10.8 |
| Debt to Equity ⓘ | 0 | 0 | 0 | 0.6 | 0.8 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0 |
| Working Cap Days ⓘ | 0 | 0 | 0 | 0 | 78 | 69 | 101 | 98 | 102 | 51 | 58 |
| Cash Conv. Cycle ⓘ | 0 | 0 | 0 | 0 | -61 | -30 | -34 | -13 | -11 | -13 | 28 |
Sales growth is growing at healthy rate in last 3 years 16.03%
Net Profit is growing at healthy rate in last 3 years 47.84%
Return on Equity has declined versus last 3 years average to 0.30%
Sales growth is not so good in last 4 quarters at 5.58%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 4.7 | 4.5 |
| TTM Sales (₹ Cr.) | 219 | 219 |
| BVPS (₹.) ⓘ | 196.8 | 196.6 |
| Reserves (₹ Cr.) ⓘ | 1,025 | 1,013 |
| P/BV ⓘ | 2.10 | 2.10 |
| PE ⓘ | 88.13 | 90.95 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 398.50 / 449.00 |
| All Time Low / High (₹) | 398.50 / 449.00 |
| Market Cap (₹ Cr.) | 2,149 |
| Equity (₹ Cr.) | 10.4 |
| Face Value (₹) | 2 |
| Industry PE ⓘ | 43.2 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|
| Sales | 70 | 99 | 157 | 140 | 223 | 190 | 219 |
| Operating Expenses ⓘ | 53 | 77 | 123 | 117 | 175 | 146 | 148 |
| Manufacturing Costs | 5 | 6 | 13 | 5 | 38 | 47 | 49 |
| Material Costs | 9 | 14 | 21 | 26 | 60 | 27 | 27 |
| Employee Cost | 11 | 19 | 32 | 23 | 34 | 40 | 40 |
| Other Costs ⓘ | 27 | 39 | 58 | 63 | 43 | 32 | 31 |
| Operating Profit ⓘ | 17 | 22 | 34 | 23 | 48 | 44 | 71 |
| Operating Profit Margin (%) | 24.8% | 22.2% | 21.7% | 16.2% | 21.5% | 23.4% | 32.4% |
| Other Income ⓘ | 1 | 1 | 2 | 1 | 2 | 4 | 4 |
| Interest ⓘ | 1 | 4 | 2 | 2 | 2 | 10 | 10 |
| Depreciation ⓘ | 6 | 9 | 13 | 16 | 15 | 32 | 33 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | -1 |
| Profit Before Tax ⓘ | 12 | 10 | 21 | 6 | 33 | 7 | 31 |
| Tax ⓘ | 4 | 5 | 6 | 0 | 9 | 1 | 8 |
| Profit After Tax | 8 | 5 | 15 | 6 | 24 | 6 | 23 |
| PAT Margin (%) | 10.8% | 5.5% | 9.7% | 4.6% | 10.6% | 3.2% | 10.6% |
| Adjusted EPS (₹) | 109.6 | 79.7 | 220.5 | 93.3 | 344.2 | 94.4 | 342.4 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | |||
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 49 | 55 | 120 | 126 | 150 | 156 | 179 | |||
| Share Capital ⓘ | 8 | 8 | 9 | 9 | 9 | 9 | 9 | |||
| Reserves ⓘ | 41 | 47 | 111 | 118 | 141 | 147 | 171 | |||
| Minority Interest | 0 | 0 | 0 | 0 | 0 | -0 | -0 | |||
| Debt | 23 | 33 | 8 | 16 | 19 | 8 | 5 | |||
| Long Term Debt | 19 | 29 | 8 | 10 | 12 | 8 | 5 | |||
| Short Term Debt | 4 | 4 | 0 | 7 | 7 | 0 | 0 | |||
| Trade Payables | 13 | 10 | 13 | 13 | 14 | 14 | 14 | |||
| Others Liabilities ⓘ | 19 | 28 | 32 | 16 | 18 | 103 | 101 | |||
| Total Liabilities ⓘ | 104 | 125 | 173 | 171 | 201 | 281 | 300 | |||
Fixed Assets | ||||||||||
| Gross Block | 88 | 116 | 194 | 198 | 211 | 226 | 274 | |||
| Accumulated Depreciation | 15 | 24 | 67 | 79 | 92 | 31 | 62 | |||
| Net Fixed Assetsⓘ | 73 | 91 | 128 | 119 | 119 | 195 | 212 | |||
| CWIP ⓘ | 0 | 0 | 0 | 0 | 1 | 2 | 1 | |||
| Investmentsⓘ | 0 | 0 | 5 | 5 | 0 | 0 | 0 | |||
| Inventories | 2 | 4 | 5 | 4 | 6 | 6 | 7 | |||
| Trade Receivables | 3 | 5 | 6 | 6 | 8 | 5 | 9 | |||
| Cash Equivalents | 12 | 9 | 4 | 4 | 3 | 55 | 55 | |||
| Others Assetsⓘ | 13 | 16 | 24 | 32 | 64 | 18 | 17 | |||
| Total Assets ⓘ | 104 | 125 | 173 | 171 | 201 | 281 | 300 | |||
| PARTICULARS | Mar'15 | Mar'16 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 20 | 13 | 31 | 24 | 42 | 44 | 60 |
| PBT ⓘ | 12 | 10 | 21 | 6 | 33 | 7 | 31 |
| Adjustment ⓘ | 6 | 12 | 14 | 21 | 16 | 40 | 41 |
| Changes in Working Capital ⓘ | 4 | -6 | 3 | -3 | -2 | 5 | -4 |
| Tax Paid ⓘ | -3 | -3 | -7 | -2 | -4 | -7 | -9 |
| Cash Flow From Investing Activity ⓘ | -42 | -26 | -20 | -28 | -44 | -21 | -35 |
| Capex | -40 | -27 | -16 | -15 | -19 | -13 | -43 |
| Net Investments | -4 | -9 | -3 | -5 | -27 | -11 | 5 |
| Others ⓘ | 2 | 10 | -1 | -7 | 2 | 3 | 3 |
| Cash Flow From Financing Activityⓘ | 17 | 10 | -10 | 3 | 1 | -24 | -25 |
| Net Proceeds from Shares ⓘ | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Paid ⓘ | -1 | -4 | -2 | -2 | -2 | -1 | -1 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 16 | 14 | -9 | 5 | 3 | -23 | -24 |
| Net Cash Flow ⓘ | -6 | -3 | 1 | -1 | 0 | -1 | 0 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 15.76 | 10.84 | 17.73 | 5.3 | 17.4 | 4.01 | 13.93 | |||
| ROCE (%) | 16.8 | 16.12 | 20.19 | 6.04 | 22.65 | 9.62 | 22.94 | |||
| Asset Turnover Ratio | 0.68 | 0.87 | 1.06 | 0.81 | 1.2 | 0.79 | 0.75 | |||
| PAT to CFO Conversion(x) | 2.5 | 2.6 | 2.07 | 4 | 1.75 | 7.33 | 2.61 | Working Capital Days | ||
| Receivable Days | 14 | 13 | 12 | 16 | 11 | 12 | 11 | |||
| Inventory Days | 11 | 11 | 11 | 13 | 9 | 12 | 11 | |||
| Payable Days | 487 | 291 | 196 | 182 | 80 | 186 | 190 | |||
Suraksha Diagnostic Limited was incorporated as ‘Suraksha Diagnostic Private Limited’ as a private limited company under the Companies Act, 1956 pursuant to a certificate of incorporation dated March 15, 2005, issued by the Deputy Registrar of Companies, West Bengal at Kolkata (RoC). Subsequently, the company was converted into a public limited company pursuant to a special resolution passed in the extra-ordinary general meeting of its Shareholders held on June 5, 2024, and consequently, the name of the company was changed to ‘Suraksha Diagnostic Limited’, and a fresh certificate of incorporation dated July 16, 2024, was issued by the Registrar of Companies, Central Processing Centre.
The company offers one-stop integrated solutions for pathology and radiology testing and medical consultation services including X-rays, ultrasonography, computerized tomography, magnetic resonance imaging scans and vaccination services through its operational network, consisting of its flagship central reference laboratory, 8 satellite laboratories (co-located with its diagnostic centers) and 215 customer touchpoints which include 49 diagnostic centres, and 166 sample collection centres (primarily franchised), as of June 30, 2024 across the states of West Bengal, Bihar, Assam, and Meghalaya. It generates revenue primarily through sales of its diagnostic services. It also provides vaccination services, and a broad spectrum of customized test packages, aimed at prediction/early detection of diseases.
In addition to integrated pathology and radiology testing services, it also offers omnichannel medical consultation services via online and offline modes to its customers. The doctors at its polyclinics range across specialties and super-specialties such as cardiology, pediatrics, dermatology, rheumatology, oncology, and nephrology. Its model of polyclinic chambers housed in diagnostic centres providing medical consultation services enables patient convenience through holistic integration of services and offering it the first right to a patient’s prescription leading to higher cross-selling opportunities to the company. It derives the majority of its revenues from the B2C segment.
Business area of the company
The company is primarily engaged in the business of running diagnostic centres for carrying out various pathological and radiological services.
Diagnostic services of the company
Awards, accreditations, and recognition
History and milestones
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
